Search results
Results from the WOW.Com Content Network
In broad usage, the "practical clinical significance" answers the question, how effective is the intervention or treatment, or how much change does the treatment cause. In terms of testing clinical treatments, practical significance optimally yields quantified information about the importance of a finding, using metrics such as effect size, number needed to treat (NNT), and preventive fraction ...
However, using patient-reported outcomes does not solve the problem of small differences being statistically significant but possibly clinically irrelevant. [6] In order to study clinical importance, the concept of minimal clinically important difference (MCID) was proposed by Jaeschke et al. in 1989. [7]
Medication that have label indications mean that they were approved by the FDA. This means that they are clinically significant for the indication and manufacturers are allowed to market their drug for the indication. [2] A drug can have more than one FDA labeled indication, which means that it can be used for multiple medical conditions. [5]
The term is most commonly used in information given to the news media, and is rarely used as a clinical description by physicians. Two aspects of the patient's state may be reported. The first aspect is the patient's current state, which may be reported as "good" or "serious," for instance. Second, the patient's short-term prognosis may be ...
The term significance does not imply importance here, and the term statistical significance is not the same as research significance, theoretical significance, or practical significance. [1] [2] [18] [19] For example, the term clinical significance refers to the practical importance of a treatment effect. [20]
A clinical trial is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials (also called medical research and research studies) are used to determine whether new drugs or treatments are both safe and effective.
Some have pointed out that a significant number of AG1 ingredients’ dosages are not disclosed on the label (49 out of 75), because they are considered “proprietary.”
Anti-Fy a is a common antibody while anti-Fy b is approximately 20 times less common., [106] [107] They are reactive at body temperature and are therefore clinically significant, although they do not typically bind complement. Antibodies are acquired through exposure (pregnancy or history of blood transfusion) and subsequent alloimmunization.